Rhumbline Advisers Reduces Holdings in AVANOS MEDICAL, INC. $AVNS

Rhumbline Advisers decreased its position in shares of AVANOS MEDICAL, INC. (NYSE:AVNS) by 4.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 137,756 shares of the company’s stock after selling 6,087 shares during the period. Rhumbline Advisers owned 0.30% of AVANOS MEDICAL worth $1,974,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in AVANOS MEDICAL during the 1st quarter worth approximately $460,000. Intech Investment Management LLC raised its stake in AVANOS MEDICAL by 154.3% during the 1st quarter. Intech Investment Management LLC now owns 124,061 shares of the company’s stock worth $1,778,000 after acquiring an additional 75,279 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in AVANOS MEDICAL by 17.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock worth $2,018,000 after acquiring an additional 20,541 shares during the period. Empowered Funds LLC raised its stake in AVANOS MEDICAL by 5.4% during the 1st quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock worth $2,324,000 after acquiring an additional 8,348 shares during the period. Finally, Caxton Associates LLP bought a new stake in AVANOS MEDICAL during the 1st quarter worth approximately $389,000. Institutional investors own 95.17% of the company’s stock.

AVANOS MEDICAL Trading Down 0.4%

AVNS stock opened at $11.85 on Thursday. The firm has a fifty day moving average price of $11.62 and a 200 day moving average price of $12.53. AVANOS MEDICAL, INC. has a fifty-two week low of $9.30 and a fifty-two week high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. The firm has a market cap of $549.61 million, a PE ratio of -1.18 and a beta of 1.12.

AVANOS MEDICAL (NYSE:AVNS) last posted its earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. The business had revenue of $175.00 million during the quarter, compared to analysts’ expectations of $165.50 million. During the same period last year, the business posted $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. Sell-side analysts anticipate that AVANOS MEDICAL, INC. will post 1.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on AVNS shares. Zacks Research upgraded shares of AVANOS MEDICAL to a “hold” rating in a research note on Tuesday, August 12th. Wall Street Zen cut shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Hold rating, According to MarketBeat, AVANOS MEDICAL presently has a consensus rating of “Hold”.

Insider Buying and Selling

In other news, Director Gary Blackford acquired 40,000 shares of the company’s stock in a transaction on Wednesday, August 13th. The stock was bought at an average cost of $10.99 per share, with a total value of $439,600.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $439,600. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.64% of the stock is owned by insiders.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.